Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019

IRVING, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and...
February 28, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results

PIVOTAL TRIALS CARDINAL AND MOXIE FULLY ENROLLED WITH DATA EXPECTED SECOND HALF 2019 FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MID-2019 CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR TODAY,...
February 21, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs

IRVING, Texas, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and...
February 20, 2019 06:45 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis and in Patients From All Four Cohorts of PHOENIX

STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION OBSERVED IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER 12 WEEKS OF TREATMENT BARDOXOLONE METHYL SIGNIFICANTLY IMPROVED KIDNEY...
January 07, 2019 07:15 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology

IRVING, Texas, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Geoffrey A. Block, M.D.,...
January 03, 2019 16:01 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

IRVING, Texas, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful...
November 07, 2018 07:00 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results and an Update on Development Programs

IRVING, Texas, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company's product development...
October 31, 2018 16:35 ET | Source: Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. to Report Third Quarter 2018 Financial Results and Provide an Update on Development Programs on Wednesday, November 7, 2018

IRVING, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that the company will report third quarter...
October 16, 2018 07:05 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018

IRVING, Texas, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s...
September 25, 2018 07:00 ET | Source: Reata Pharmaceuticals, Inc.

Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in IgA Nephropathy and Type 1 Diabetic Chronic Kidney Disease

Statistically Significant Improvement in Kidney Function Observed in Both Diseases After 12 Weeks of Treatment Conference Call with Management Scheduled for Today at 8:00 am ET IRVING, Texas, Sept. ...